IMRIS Inc. (IMRSQ) Stock
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About IMRIS Inc.
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Minnetonka, Minnesota.
IMRIS Inc. is led by CEO Marc Buntaine, employs 121 people, headquartered in Minnetonka, US, publicly traded since 2023.
the stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, IMRIS Inc. generates a return on equity (ROE) of -250.00%, return on capital employed of -68.54%, an operating margin of -79.31%, a net profit margin of -103.45%.
Official website: www.imris.com